GENDER DIFFERENCES IN CHEMOTHERAPY-INDUCED ALOPECIA DISTRESS USING THE JAPANESE VERSION OF THE CHEMOTHERAPY-INDUCED ALOPECIA DISTRESS SCALE (CADS-J)



Hiroki Okumura 1), Shuko Soma 2), Yosuke Aoyama 3), Yu Harada 2), Kiyomi Nonogaki 1), Haruka Ozaki 1), Haruka Ozaki 1), Masahiro Kuno 1), Shogo Watanabe 1), Kazumasa Yamamoto 1), Kohji Takemura 1), Takeshi Yamaguchi 1), Yuko Tanabe 1), Atsushi Yokoyama 2), Koichi Suyama 1), Koji Hashiguchi 2), Yuji Miura 1)

1) Toranomon Hospital, Department of Medical Oncology, Tokyo, Japan, 2) Yokohama Minami Kyosai Hospital of the Japanese Foundation for Cancer Research, Breast Oncology Center, Department of Breast Medical Oncology, Tokyo, Japan

Background

- ✓ Chemotherapy-induced alopecia (CIA) is one of the most important concerns of cancer patients.
- There have been few studies on patients with cancers other than breast cancer or patients including men
- √ The CADS (Chemotherapy-induced Alopecia Distress Scale) was reported in 2014 as a patient-reported outcome module to assess the quality of life of patients with cancer¹⁾. This test paper is a 4-module, 17-question with a max of 51 points.
- ✓ The CADS-J was created in Japan in 2023²⁾
- ✓ The objective of this study is to examine gender differences in distress of CIA in Japanese cancer patients using CADS-J.

men er er en enpaneer eaneer paneine aenig ette ei					
	Number of questions	Content of questions			
Physical	2	Itching and pain at the site of hair loss			
Emotional	6	Feeling different, dissatisfaction with appearance, anxiety about the future, stress, depressed mood, loneliness			
Activity	6	Difficulty washing hair, limited leisure time, awareness of being sick, hesitant to go shopping, wearing wigs			
Relationship	3	Anxiety about relationships with family and friends, relationships with partners and sexual relationships with partners			

Patients and methods

- ✓ A prospective questionnaire study was conducted at Toranomon Hospital and Yokohama Minami Kyosai Hospital from March 2023 to December 2023
- Subjects had to be:
- 1. Eighteen years of age or older.
- 2. Never experienced chemotherapy-induced alopecia in the past and have chemotherapy-induced alopecia currently.
- 3. Obtained written consent.
- The degree of chemotherapy-induced alopecia was not limited to any degree, but the coexistence of non-chemotherapy-induced alopecia was allowed. Combination chemotherapy with molecularly targeted agents or immune checkpoint inhibitors was allowed.
- Methods for assessing the degree of alopecia are Dean scale and CTCAE, were used to assess patients' alopecia.
- Questionnaires were distributed to 104 people, and valid responses were received from 97 (response rate was 93.2%).

Statistical analysis

- T-test, Fisher's exact test, and multivariate analysis with linear regression
- The statistical software was SPSS.
- The six variables for multivariate analysis were gender, age, CTCAE scale, wearing a wig/hat, working status, and depression, based on previous studies.

Results

Table 1. Patient characteristics

	Charac	cteristics	Male (n=55, 56.7%)	Female (n=42, 43.3%)	p-value
Age, years, mean (SD) (total 62.6, SD=12.7)		64.0 (13.2)	60.7 (12.1)	0.20	
Satting.		Metastatic	51 (92.7%)	21 (50%)	<0.001
Settin	9	Perioperative	4 (7.3%)	21 (50%)	
Regimen		Taxane	28 (50.9%)	28 (66.7%)	0.091
		Irinotecan	15 (27.3%)	4 (9.5%)	
		Others	12 (21.8%)	10 (23.8%)	
		1	9 (16.4%)	1 (2.4%)	0.015
	Deen	2	7 (12.7%)	1 (2.4%)	
Degree of	Dean	3	8 (14.5%)	5 (12.0%)	
hair loss		4	31 (56.4%)	35 (83.3%)	
	CTCAE	1	16 (29.1%)	2 (4.8%)	0.0030
	CTCAE	2	39 (70.9%)	40 (95.2%)	
Dunyinun ha	in lane	None	23 (41.8%)	26 (62.0%)	0.077
Previous ha		Slight	27 (49.1%)	11 (26.2%)	
before cheme	otnerapy	Significant	5 (9.1%)	5 (12.0%)	
Weering o	uia/bat	No	31 (56.4%)	1 (2.4%)	<0.001
Wearing a v	wig/nat	Yes	24 (43.6%)	41 (97.6%)	
		Working	13 (23.6%)	9 (21.4%)	1.00
Working status		Retired/housewife/ leave of absence	42 (76.4%)	33 (78.6%)	
		Less than 3 million yen	18 (35.3%)	7 (17.5%)	0.18
Monthly famil	y income	3-6 million yen	15 (29.4%)	14 (35.0%)	
-		More than 6 million yen	18 (35.3%)	19 (47.5%)	
Marital at	entura	Married	38 (69.1%)	10 (23.8%)	0.50
Marital st	atus	Single/Separated	17 (30.9%)	32 (76.2%)	
Educati		High school graduate	15 (27.3%)	14 (33.3%)	0.66
Educati	On	More than college	40 (72.7%)	28 (66.7%)	
Religion		None	31 (59.6%)	32 (80.0%)	0.055
		Buddhism	18 (34.6%)	8 (20.0%)	
		Others	3 (5.8%)	0 (0%)	
Dammara	lan.	CES-D <16	34 (61.8%)	27 (64.3%)	0.84
Depression		CES-D ≧16	21 (38.2%)	15 (35.7%)	
		0L0 D = 10	21 (00.270)	10 (00.1 /0)	

- There was a significant difference between male and female patients in the metastatic setting.
- The degree of alopecia was more severe in females than in males.
- Women were significantly more likely to require a wig/ hat due to hair loss.


In all domains, women

Table 2. Gender differences in CADS physical mean, emotional, activity, relationship, and total score

	Male	Female	p-value
CADS physical mean (SD) (Male 55 (100%), Female 42 (100%)	0.27 (0.53)	0.81 (1.17)	0.0032
CADS emotional mean (SD) (Male 55 (100%), Female 42 (100%)	2.25 (2.16)	4.86 (3.61)	<0.001
CADS activity mean (SD) (Male 55 (100%), Female 42 (100%)	3.21 (2.66)	6.38 (3.00)	<0.001
CADS relationship mean (SD) (Male 45 (81.8%), Female 39 (92.9%)	0.25 (0.78)	0.85 (1.29)	0.012
CADS total mean (SD) (Male 45 (81.8%), Female 39 (92.9%)	5.66 (5.31)	13.15 (7.08)	<0.001

- scored significantly higher; the mean was 5.66 vs. 13.15 points.
- 18.2% of women and 7.1% of men were deficient in the relationship domain question.

- Figure 1. Histogram of CADS scores for men and women
- The distribution of scores by gender is shown, and although the distribution is more skewed to the right for men than for women, some men felt much more distress than the average score



- 5/55 (9.1%) men had a CADS total score of 13 (average for women) or
- All had metastatic recurrence, 4 had CTCAE grade 2 hair loss, and 4 wore
- There was no consistent trend in other background factors.

Table 3. Univariate and multivariate analysis of CADS total score

	Univariate regression coefficient (95%CI)	p-value	Multivariate regression coefficient (95%CI)	p-value
Gender	7.50 (4.78, 10.21)	p=0.00000045	3.46 (0.56, 6.36)	p=0.020
Age	-0.20 (-0.40, -0.0027)	p=0.047	-0.28 (-2.73, 2.17)	p=0.82
CTCAE scale	6.37 (2.69, 10.04)	p=0.00089	0.270 (-3.14, 3.68)	p=0.88
Wearing a wig/hat	8.95 (6.24, 11.66)	p=0.000000046	6.19 (2.89, 9.49)	p=0.00036
Working status	1.09 (-1.01, 3.20)	p=0.31	1.62 (-1.27, 4.51)	p=0.27
Depression (CES-D ≧16)	6.51 (3.50, 9.51)	p=0.000045	5.62 (3.24, 8.01)	p=0.000012

- Univariate analysis showed that gender, age, CTCAE scale, wearing a wig/hat, and depression were significantly related to CADS total score.
 - Multivariate analysis showed that wearing a wig/hat and depression were significantly related to CADS total score.

Limitations

- ✓ ① In comparing gender differences, the number of women was smaller. Most of the female patients were in the perioperative period of breast cancer, resulting in Dean grade 4 and CTCAE grade 2 alopecia, and there were gender differences in the severity of alopecia.
- ✓ 2 The results showed about 10% of patients with hair loss in the domain of "Relationship." We had told them to fill in this domain if they had a partner at the time of distribution, but the domain was missing if they did not have a partner or did not wish to fill in the domain.

Discussions

- ✓ This is the first study to quantitatively and qualitatively assess CIA distress and compare gender differences. ✓ A certain number of men in this study had distress associated with hair loss.
- There are multiple male-specific issues related to chemotherapy-induced hair loss. Interviews with male and female breast cancer patients⁴⁾ reported that men were forced to reveal their hair loss status while women were able to conceal their hair loss. In addition, interviews with men and women who experienced chemotherapy-induced hair loss
- in the United Kingdom⁵⁾ indicated that only women were encouraged by others to prevent or disguise their hair loss. In the future, it will be necessary to use CADS and other tools for reporting patient-reported outcomes to disaggregate patients' hair loss distress, identify points for further intervention in hair loss distress, and provide appropriate intervention for men as well.

References

- Ann Oncol. 2014 Feb;25(2):346-51.
- Breast Cancer, 2024 Mar:31(2):234-242.
 - Eur J Oncol Nurs. 2013 Jun;17(3):255-60.
 - Cancer Nurs. 2021 Jan/Feb;44(1):62-70.
 - 5) Psychooncology. 2008 Jun;17(6):577-83.